- Home
- EVAX vs ENSC Comparison
EVAX vs ENSC Comparison
Compare EVAX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- ENSC
- Stock Information
- Founded
- EVAX 2008
- ENSC 2003
- Country
- EVAX Denmark
- ENSC United States
- Employees
- EVAX N/A
- ENSC N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- ENSC Health Care
- Exchange
- EVAX Nasdaq
- ENSC Nasdaq
- Market Cap
- EVAX 15.1M
- ENSC 4.9M
- IPO Year
- EVAX 2021
- ENSC N/A
- Fundamental
- Price
- EVAX $2.65
- ENSC $2.15
- Analyst Decision
- EVAX Strong Buy
- ENSC
- Analyst Count
- EVAX 2
- ENSC 0
- Target Price
- EVAX $10.00
- ENSC N/A
- AVG Volume (30 Days)
- EVAX 104.8K
- ENSC 59.4K
- Earning Date
- EVAX 08-13-2025
- ENSC 08-13-2025
- Dividend Yield
- EVAX N/A
- ENSC N/A
- EPS Growth
- EVAX N/A
- ENSC N/A
- EPS
- EVAX N/A
- ENSC N/A
- Revenue
- EVAX $3,293,000.00
- ENSC $6,224,081.00
- Revenue This Year
- EVAX N/A
- ENSC N/A
- Revenue Next Year
- EVAX N/A
- ENSC $1,381.48
- P/E Ratio
- EVAX N/A
- ENSC N/A
- Revenue Growth
- EVAX 2555.64
- ENSC 256.35
- 52 Week Low
- EVAX $1.20
- ENSC $1.62
- 52 Week High
- EVAX $17.75
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- EVAX 55.56
- ENSC 46.61
- Support Level
- EVAX $2.26
- ENSC $1.97
- Resistance Level
- EVAX $2.60
- ENSC $2.40
- Average True Range (ATR)
- EVAX 0.21
- ENSC 0.16
- MACD
- EVAX -0.02
- ENSC 0.00
- Stochastic Oscillator
- EVAX 51.32
- ENSC 44.19
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.